Tempus

Tempus

Tempus is a technology company building the largest library of clinical and molecular data to power AI-driven precision medicine. It provides genomic sequencing and data analytics services to healthcare providers and life sciences companies, focusing on oncology, cardiology, neurology, and digital pathology. The platform integrates comprehensive patient data to generate actionable insights for clinical decision-making and research. Key capabilities include whole-genome sequencing, RNA sequencing, comprehensive genomic profiling, and a large multimodal dataset for AI model development. Its products like Hub and Olivia offer AI-enabled clinical assistance and data exploration tools. Tempus serves oncologists, pathologists, neurologists, cardiologists, and researchers in academic and life sciences organizations.

Search
Visit website
Added on
Sep 22, 2026
Precision MedicineGenomic SequencingAI DiagnosticsClinical Data PlatformLife Sciences Research
Product information

Everything worth knowing about Tempus

The complete picture — from everyday features to the technical detail builders and IT folks dig for.

Core features

What it actually does

Oncology & Multi-Specialty Testing
Provides diagnostic tests and clinical decision support across oncology, neurology, cardiology, and pathology.
AI-Enabled Clinical Platform (Hub)
Securely access patient information, place orders, track results, and receive AI-assisted therapy updates.
Data & AI Products for Life Sciences
Offers data licensing, AI models, and analytics for pharmaceutical and biotech research.
Clinical Trial Recruitment & Operations
Services to identify patient cohorts and manage clinical trial logistics.
Technical capabilities
Multimodal Genomic & Clinical Data
Operates on a large, proprietary dataset combining genomic, clinical, and imaging data.
Foundation Models & Algos
Develops proprietary foundation models and algorithms for data analysis and predictive insights.
Must watch videos
Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI
4:44
Tutorial4:44
Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI
Eric Lefkofsky, Tempus AI founder and CEO, joins 'The Exchange' to discuss AI's role in healthcare, advancing cancer research with AI, personalized vaccines, and more. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/42d859g » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Watch CNBC on the go with CNBC+: https://www.cnbc.com/WatchCNBCPlus Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC Follow CNBC on Threads: https://cnb.cx/threads Follow CNBC News on X: https://cnb.cx/FollowCNBC Follow CNBC on WhatsApp: https://cnb.cx/WhatsAppCNBC https://www.cnbc.com/select/best-credit-cards/ #CNBC #CNBCTV
Tempus Overview
3:30
Tutorial3:30
Tempus Overview
Tempus was started by Eric Lefkofsky with the understanding of how critical it is to bring technology to the very physicians who are seeing patients everyday. Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Learn how Tempus is working to impact people and help change the lives of people across the world. Join us as we work to change the world. Join our mission: https://tempus.co/3vRirNX Contact us to learn more about Tempus: https://tempus.co/3v33AgS Chicago Ave Ste #510 Chicago, IL 60654 Call (833) 514-4187
Tempus AI ($TEM): The Palantir of Healthcare? | Full Investment Analysis
29:28
Tutorial29:28
Tempus AI ($TEM): The Palantir of Healthcare? | Full Investment Analysis
After spending the past several weeks researching Tempus AI ($TEM), I came away thinking this is much more than a genomics company. I believe Tempus is attempting to build the data and intelligence layer for precision medicine—combining diagnostics, AI, genomics, clinical data, and pharmaceutical partnerships into a single platform that could become foundational infrastructure for healthcare. In this deep dive, I analyze Tempus using my six-factor investing framework: • Product Advantage • Structural Tailwinds • Management Execution • Competitive Moat • Financial Trajectory • Risk Awareness We discuss: Why some investors call Tempus the “Palantir of Biology” The company’s unique healthcare data advantage AstraZeneca’s $200M partnership The Personalis acquisition Revenue growth and profitability Cash flow and valuation The biggest risks investors need to understand My own investment plan and price target for initiating a position Healthcare may ultimately become one of the largest beneficiaries of artificial intelligence. The question is whether Tempus can become one of the companies enabling that transformation. As always, this is not financial advice. These videos simply document my own research process and investing framework. If you enjoy deep-dive analysis on AI, technology, and emerging industries, consider subscribing. Chapters 00:00 Introduction 02:00 Why Healthcare Now? 05:46 The Story 07:08 Product Advantage 11:39 Structural Tailwinds 13:39 Management & Execution 17:05 Moat 19:28 Financials 22:47 Risks 25:28 Final Thoughts & Would I Buy? Tempus AI TEM Stock Tempus Stock Analysis TEM Analysis Tempus AI Stock Healthcare AI Artificial Intelligence Stocks Precision Medicine Genomics Healthcare Technology AI Investing AI Stocks Palantir Healthcare Palantir of Biology Drug Discovery AI Medical AI AstraZeneca Personalis Ambry Genetics AI Healthcare Stocks Growth Stocks Long Term Investing Stock Analysis Investment Thesis ⚠️ If you enjoy high-quality analysis on AI and tech stocks, subscribe for more. Disclaimer: This video is for informational purposes only and is not financial advice. X: https://x.com/borex_investing

Who uses it

Real use cases, no hype
Clinical Trial Matching
Identify eligible patients from institutional data for specific clinical trials.
Precision Oncology
Match cancer patients to targeted therapies based on comprehensive genomic profiling.
Research Data Access
License de-identified multimodal data (genomic, clinical, imaging) for drug discovery and AI research.
Digital Pathology Analysis
Leverage AI to analyze whole-slide images for diagnostic and predictive insights.
Cardiac AI Deployment
Utilize autonomous AI tools for cardiology, supported by recent ARPA-H funding.
Operational Analytics
Use platform insights to optimize diagnostic lab workflows and operational efficiency.
What's great
  • Vast clinical data ecosystem across multiple specialties.
  • AI-driven clinical decision support via the Hub platform.
  • Integrated lab services for genomic and digital pathology testing.
  • Global operational footprint across 30+ countries.
Technical strengths
  • Proprietary foundation models for RNA and multimodal analysis.
  • Tight EHR integration for seamless clinical workflow.
Where it falls short
  • Pricing not transparent; requires direct contact for quotes.
  • Primarily focused on oncology and specific disease areas.
  • Services are for institutions, not individual developers.
  • Complex, multi-product platform may have a steep learning curve.
Technical limitations
  • Heavy reliance on proprietary data formats and APIs.
For technical folks

The deep-dive specs

FAQ

Includes technical Q&A
You must contact sales directly. Pricing is not listed publicly and is customized based on institutional needs, test volume, and data licensing agreements.

Traffic Insights

Monthly Visits

—

November 2026

Growth Rate

0%

vs last month

Dominance

0%

in Search

Top Country

—

Top Countries Breakdown

—

Growth Trend

Stable

Traffic has remained stable.

Pricing overview
Paid Pricing

Tempus Pricing

Tempus uses a paid pricing structure. Real-time rates, custom enterprise quotas, and plan details are managed directly on their official platform.

Check Pricing on Tempus
Reviews

What the internet actually thinks

Data refreshed weekly. No paid placements.

Trustpilot
Not reviewed yet
G2
G2
Not reviewed yet
C
Capterra
Not reviewed yet
Product Hunt
Not reviewed yet
COMMUNITY COMMENTS

Leave a Comment

Help others make informed decisions. Your honest feedback shapes the community's understanding of this tool.

Tips for commenting

  • •Be specific about features you used
  • •Share real use cases and results
  • •Mention both pros and cons
  • •Keep it honest and constructive
to leave a comment

Your comment is published immediately.

Filter:
Sort:

No comments yet

Be the first to share your experience with this tool.

Alternatives

Not quite the right fit?

Here's what else is out there.